Welcome to the OPTIMA Clinical Trial
For people with fibrodysplasia ossificans progressiva
Welcome!
Clinical trials are essential to developing treatments – we wouldn’t be able to develop treatments without volunteers like you. Everyone involved in this clinical trial plays an important role in increasing our understanding of FOP, which may help other patients in the future with this condition.
Why are we doing this clinical trial?
FOP is an extremely rare genetic disease characterised by abnormal bone growth in areas of the body where bone is normally not present (called heterotopic ossification), such as the ligaments, tendons and skeletal muscles. People with FOP may also experience “flare-ups” that are unpredictable episodes of soft tissue swelling, pain, stiffness and reduced movement. Flare-ups may sometimes lead to additional bone formation.
The OPTIMA Clinical Trial is testing an investigational drug as a potential treatment in people with FOP. The trial drug being tested is called “investigational” because it hasn’t been approved for use outside of this clinical trial.
In this clinical trial, researchers want to find out if the investigational drug can help reduce signs and symptoms of FOP, such as the number of flare-ups and amount of abnormal bone growth.
How is the investigational drug believed to work?
Who can take part in the OPTIMA Clinical Trial?
18 years old or older
Diagnosed with FOP
Experiencing signs and symptoms associated with FOP flare-ups (such as pain, swelling, or stiffness) in the last year
What else should I know?
There is no guarantee that you will receive a medical benefit from taking part in this clinical trial. Your condition may get better, stay the same or may get worse. The trial drug may also cause side effects or affect your health in an unknown way. However, your safety is our top priority and your health will be closely monitored throughout the OPTIMA Clinical Trial.